FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C.	20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Molineaux Christopher P.					2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]								ck all applica	,		on(s) to Issu 10% Ov							
	•	First) ERAPEUTICS, I JITE 200	(Middle)	(3. Date of Earliest Transaction (Month/Day/Year) 06/04/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)								Officer (give title below)			Other (s below)	pecify						
(Street) WAYNE	P.	A	19087							Line)	7 3 (11												
(City)	(S	State)	(Zip)																				
1. Title of Security (Instr. 3) 2. Trans Date			2. Transact	Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		uired, Disposed of, or Benefici 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of (D) (Instr. 3, 4 and Code (Instr. 3)			(A) or	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership									
						00,100,10	Code	v	Amount	(D)		(Instr. 3 ar	Transaction(s) (Instr. 3 and 4)			(Instr. 4)							
				06/06/2				M		7,333	A		(1) 23,891			D							
			Table II - D (e							osed of, o onvertibl			wned										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y		isable and 7. Title and Ai te of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)						
				Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)									
Option Grant (right to buy)	\$1.41	06/04/2020		A		16,500		(2)		(2)		(2)		(2)		06/03/2030	Common Stock	16,500	\$0.00	16,50	00	D	
Restricted Stock Units	(1)	06/06/2020		М			7,333 ⁽³⁾	(4)		(4)	Common Stock	7,333	\$0.00	0		D							

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 2. The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date.
- 3. This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy.
- ${\it 4. The shares underlying these restricted stock units vested on June \, 6, \, 2020.}\\$

Remarks:

/s/ Mark Ballantyne, Attorneyin-fact 06/08/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.